MCID: NRV007
MIFTS: 66

Nervous System Disease

Categories: Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Nervous System Disease

MalaCards integrated aliases for Nervous System Disease:

Name: Nervous System Disease 12 15 17
Abnormality of the Nervous System 6
Nervous System Diseases 43
Nervous System Disorder 71

Classifications:



External Ids:

Disease Ontology 12 DOID:863
ICD9CM 34 349.9
MeSH 43 D009422
NCIt 49 C26835
UMLS 71 C0027765

Summaries for Nervous System Disease

Disease Ontology : 12 A disease of anatomical entity that is located in the central nervous system or located in the peripheral nervous system.

MalaCards based summary : Nervous System Disease, also known as abnormality of the nervous system, is related to central nervous system disease and peripheral nervous system disease, and has symptoms including seizures, ataxia and tremor. An important gene associated with Nervous System Disease is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are PEDF Induced Signaling and Cytokine Signaling in Immune system. The drugs Etomidate and Oseltamivir have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, peripheral nervous system and brain, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Nervous System Disease

Diseases in the Nervous System Disease family:

Autoimmune Disease of Central Nervous System Congenital Nervous System Abnormality
Central Nervous System Disease Infectious Disease of the Nervous System

Diseases related to Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1238)
# Related Disease Score Top Affiliating Genes
1 central nervous system disease 35.9 TNF TBK1 SERPINA3 PROM1 NOS2 MOG
2 peripheral nervous system disease 35.6 TNF SERPINA3 MOG IL6 IL1B IFNG
3 amyotrophic lateral sclerosis 1 33.8 TBK1 SERPINA3 NOS2 MIR9-1 H2AC18 CRYAA
4 multiple sclerosis 33.6 TNF NOS2 MOG MMP9 IL6 IL1B
5 meningitis 33.6 TNF MMP9 IL6 IL1B IFNG CSF2
6 meningoencephalitis 33.4 TNF IL6 CCR6
7 toxic encephalopathy 33.0 TNF SERPINA3 MIR9-1 IL6 IL1B H2AC18
8 acute disseminated encephalomyelitis 32.2 MOG IL1B CCR6
9 encephalitis 32.1 TNF NOS2 MOG IL6 IL1B
10 neuromuscular disease 32.1 TNF SERPINA3 IL6 H2AC18 CRYAA CCR6
11 systemic lupus erythematosus 32.0 TNF MMP9 IL6 IL1B IFNG H2AC18
12 demyelinating disease 31.9 TNF SERPINA3 MOG MMP9 MIR9-1 IL6
13 autoimmune disease 31.9 TNF MOG MMP9 IL6 IL1B IFNG
14 acquired immunodeficiency syndrome 31.8 TNF NOS2 IL6 IL1B IFNG CSF2
15 immune deficiency disease 31.7 TNF IL6 IFNG H2AC18 CSF2 CCR6
16 neuritis 31.7 TNF MOG MMP9 IL6 IL1B IFNG
17 measles 31.7 TNF IL6 IL1B IFNG
18 neuromuscular junction disease 31.7 SERPINA3 H2AC18 CCR6
19 leukemia, acute myeloid 31.7 TNF SERPINA3 PROM1 MIR9-1 IL6 H2AC18
20 bacterial meningitis 31.7 TNF MMP9 IL6 IL1B IFNG CSF2
21 histiocytosis 31.6 TNF SERPINA3 CSF2 CCR6
22 viral encephalitis 31.6 TNF MOG IL6 IL1B CCR6
23 stomatitis 31.6 TNF IL6 IL1B IFNG CSF2
24 myelitis 31.6 TNF MOG MMP9 IL6 CCR6
25 toxoplasmosis 31.6 TNF NOS2 IL6 IL1B IFNG
26 aseptic meningitis 31.5 TNF IL1B IFNG
27 subacute sclerosing panencephalitis 31.5 TNF MOG IL6 IFNG
28 optic neuritis 31.5 TNF MOG IL1B CXCR3
29 spinal cord injury 31.5 TNF NOS2 MMP9 IL6
30 chickenpox 31.5 TNF IL6 IFNG CCR6
31 leukemia, acute lymphoblastic 31.4 PROM1 MIR9-1 H2AC18 CSF2 CCR6
32 sarcoidosis 1 31.4 TNF SERPINA3 IL1B IFNG CXCR3 CCR6
33 optic nerve disease 31.4 TNF SERPINA3 MOG IL6 CRYAA CCR6
34 migraine with or without aura 1 31.4 TNF IL6 IL1B H2AC18
35 psoriatic arthritis 31.4 TNF IL6 IL1B IFNG CCR6
36 relapsing-remitting multiple sclerosis 31.3 TNF MOG MMP9 IL6 IL1B IFNG
37 trypanosomiasis 31.3 TNF NOS2 IL6 IL1B IFNG CXCR3
38 viral meningitis 31.3 IL6 IFNG CXCR3
39 myeloma, multiple 31.3 TNF MMP9 IL6 IFNG H2AC18 CSF2
40 vascular disease 31.3 TNF NOS2 MMP9 IL6 IFNG
41 toxic shock syndrome 31.3 TNF NOS2 IL6 IL1B IFNG
42 spinal cord disease 31.3 TNF MOG IL6 H2AC18 CCR6
43 vascular dementia 31.3 TNF SERPINA3 MMP9 IL6 IL1B
44 bacterial sepsis 31.2 TNF NOS2 IL6 CCR6
45 allergic hypersensitivity disease 31.2 TNF IFNG H2AC18 CSF2 CCR6
46 polyradiculopathy 31.2 TNF IL6 IL1B
47 crohn's disease 31.1 TNF IL6 IL1B IFNG CCR6
48 lyme disease 31.1 TNF MMP9 IL6 IL1B
49 eye disease 31.1 TNF SERPINA3 MMP9 MIR9-1 IL6 IL1B
50 inflammatory bowel disease 31.1 TNF NOS2 MMP9 IL6 IL1B IFNG

Comorbidity relations with Nervous System Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Nervous System Disease:



Diseases related to Nervous System Disease

Symptoms & Phenotypes for Nervous System Disease

UMLS symptoms related to Nervous System Disease:


seizures, ataxia, tremor, myoclonus, gait ataxia, back pain, ophthalmoplegia, vertigo, pain, agitation, headache, clumsiness, involuntary movements, dysdiadochokinesis, action tremor, bradykinesia, hemiplegia, torticollis, muscle fibrillation, syncope, hyperesthesia, hemiparesis, athetosis, opisthotonus, asterixis, cogwheel rigidity, dysesthesia, scalp tenderness, hyperalgesia, chronic pain, sciatica, astasia, cheyne-stokes respiration, hoarseness, vertigo/dizziness, equilibration disorder, sleeplessness, muscular fasciculation, symptoms, muscle rigidity, muscle spasticity, spasm, cerebellar ataxia, numbness, numbness localized, agitation mental, numb mouth, clouded consciousness, meningism, reflex, abnormal, spasmodic torticollis, dizziness, akathisia, neuralgia, adiadochokinesis, decreased tendon reflex, musculoskeletal symptom, circumoral paresthesia, pathological conditions, signs and symptoms, asynergia, dyskinesia neonatal, staggering gait, non-epileptic convulsion, absence attacks, lid retraction, micropsia, leg cramps, lassitude, spasm oropharyngeal, aphonia, flaccid muscle tone, flaccid paralysis, burning sensation, hypalgesia, lightheadedness, muscular stiffness, muscular incoordination, fine tremor, coarse tremor, epileptic aura, fumbling, head discomfort, head pressure, head tightness, hypersensation skin, bulging fontanelle, neurologic symptoms, paresthesia, distal, paresthesia mucosal, paresthesia skin, tingling of skin, skeletal muscle paralysis, paralysis muscle general skeletal, paralysis muscle local skeletal, paralysis lower motor neuron type, scotoma, scintillating, tongue sluggish, tremor, perioral, tremor, limb, tremor, muscle, nerve tremors, tremor, neonatal, anesthesia mouth, anesthesia lip, anesthesia oral mucosa, anesthesia tongue, burning sensation of skin, post-lumbar puncture headache, tonic seizures, extreme exhaustion, rigor - temperature-associated observation, burning mucosal, paresthesia mouth, eyes rolling, electric shock sensation, jaw stiffness, muzzy headed, motor restlessness, myotonus (finding), reaction to spinal or lumbar puncture, headache fullness

MGI Mouse Phenotypes related to Nervous System Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.15 CCR1 CCR6 CSF2 CXCR3 IFNG IL1B
2 hematopoietic system MP:0005397 10.1 CCR1 CCR6 CSF2 CXCR3 IFNG IL1B
3 immune system MP:0005387 10.03 CCR1 CCR6 CSF2 CXCR3 IFNG IL1B
4 neoplasm MP:0002006 9.81 CSF2 CXCR3 IFNG IL1B IL6 MMP9
5 renal/urinary system MP:0005367 9.56 CCR1 CSF2 CXCR3 IFNG IL6 MMP9
6 respiratory system MP:0005388 9.23 CCR1 CSF2 CXCR3 IFNG IL6 MMP9

Drugs & Therapeutics for Nervous System Disease

Drugs for Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 567)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etomidate Approved Phase 4 33125-97-2 36339 667484
2
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Norepinephrine Approved Phase 4 51-41-2 439260
5
Memantine Approved, Investigational Phase 4 19982-08-2 4054
6
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
7
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
8
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
9
Vigabatrin Approved Phase 4 60643-86-9, 68506-86-5 5665
10
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
11
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
12
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
13
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
16
Ziconotide Approved Phase 4 107452-89-1 447451
17
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
18
Zidovudine Approved Phase 4 30516-87-1 35370
19
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
20
Nevirapine Approved Phase 4 129618-40-2 4463
21
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
22
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
23
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
24
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
25
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
26
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
27
Histamine Approved, Investigational Phase 4 51-45-6 774
28
Lithium carbonate Approved Phase 4 554-13-2
29
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
30
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
31
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
32
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
33
Tapentadol Approved Phase 4 175591-23-8 9838022
34
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
35
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
36
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
37
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
38
Choline Approved, Nutraceutical Phase 4 62-49-7 305
39
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
40
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
41
Cobalamin Experimental Phase 4 13408-78-1 6857388
42
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
43
Cortisone Experimental Phase 4 53-06-5 222786
44 Antineoplastic Agents, Hormonal Phase 4
45 Dopamine Agents Phase 4
46 Nootropic Agents Phase 4
47 Antiparkinson Agents Phase 4
48 Excitatory Amino Acids Phase 4
49 Excitatory Amino Acid Antagonists Phase 4
50 Hypnotics and Sedatives Phase 4

Interventional clinical trials:

(show top 50) (show all 1262)
# Name Status NCT ID Phase Drugs
1 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
2 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial Unknown status NCT00123136 Phase 4
3 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
4 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
5 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
6 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
7 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
8 Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients Completed NCT00560157 Phase 4
9 Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
10 Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function Completed NCT01662414 Phase 4
11 A Randomized, Single-dose, Parallel-group Study to Evaluate the Pharmacokinetic Profiles of Two Formulation of Pregabalin in Healthy Volunteers Under Fasting Conditions Completed NCT03712475 Phase 4 Pregabalin
12 An Open Label Extension Safety Trial of Pregabalin (CI-1008) in Subjects With Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
13 A 14-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Pregabalin (150mg-600mg/Day) Using A Flexible Optimal Dose Schedule In Patients With Painful Diabetic Peripheral Neuropathy (DPN). Completed NCT00156078 Phase 4 pregabalin
14 Use of Dexmedetomidine for Prophylactic Analgesia and Sedation in Patients After Intracranial Surgery (Prophylactic Analgesia and Sedation Trial, PASTrial) Completed NCT01445639 Phase 4 Dexmedetomidine;Normal saline
15 A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
16 The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study Completed NCT02056366 Phase 4 α-lipoic acid
17 A Prospective, Open-label Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®) Completed NCT01278173 Phase 4 Sabril
18 Comparison of the Analgesic Effect of the Local Anesthetics Ropicacaine, Levobupivacaine, and Levobupivacaine + Epinephrin Via Interscalene Nerve Block in Patients Undergoing Shoulder Arthroscopy Under General Anesthesia Completed NCT02691442 Phase 4 Ropivacaine 0.75%;Levobupivacaine 0.5%;Levobupivacaine 0.5% + epinephrin 1/200000
19 A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
20 A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
21 A 24 Week, Double-blind, Placebo-controlled, Multisite Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
22 An Open-label, Randomized, Multi-center Clinical Trial to Evaluate the Safety and Efficacy in Peripheral Neuropathies Patients Treated With Mecobalamin Injection Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
23 Efficacy and Safety of Pregabalin in an Open-label, Non-comparative, Flexible-dose Trial With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
24 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
25 Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study Completed NCT01373983 Phase 4 Ziconotide
26 Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China Completed NCT01340950 Phase 4 zidovudine-lamivudine-nevirapine;tenofovir-lamivudine-efavirenz
27 A Phase IV Clinical Trial. Effect of Pulsing Electromagnetic Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
28 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
29 A Randomized, Double-Blind, Placebo-Controlled, Single Center Study Designed to Assess the Effects of Pregabalin on Change in Patients With Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
30 Sympathetic Heart Innervation in Patients With Previous Experience of Transient Stress-induced Cardiomyopathy (Tako-Tsubo): Effects of α-lipoic Acid and L-acetyl Carnitine Therapies. Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
31 A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment Completed NCT01675531 Phase 4 Targin
32 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
33 Comparison of the Effectiveness and Safety Between Tramadol 37.5 Mg/Acetaminophen 325mg And Gabapentin for The Treatment of Painful Diabetic Neuropathy: Multicenter, Randomized, Open Comparative Study Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
34 Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial Completed NCT02923388 Phase 4 Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
35 Study of Memantine to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Monocentric Trial Completed NCT01108029 Phase 4 memantine;placebo
36 Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial Completed NCT00914095 Phase 4 methylphenidate;placebo
37 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
38 The Facial Nerve Palsy And Cortisone Evaluation (FACE) Study in Children: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Recruiting NCT03781700 Phase 4 Prednisolone;Placebo Oral Tablet
39 Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) Recruiting NCT02684825 Phase 4
40 Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics Recruiting NCT03219008 Phase 4 Fluoxetine;fluoxetine + Amfebutamone;Fluvoxamine;Lithium+fluvoxamine;Mirtazapine/SNRIs;mirtazapine + SNRIs
41 A Double-blind, Placebo-controlled, Cross-over Study of Ranolazine in Patients With Coronary Artery Disease for the Treatment of Painful Polyneuropathy Terminated NCT00832572 Phase 4 Ranolazine;Placebo
42 Phase 4 Study of Tapentadol vs Oxycodone in Neuropathic Pain Terminated NCT01458015 Phase 4 tapentadol, oxycodone
43 Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Terminated NCT00867815 Phase 4 Diagnostic procedures
44 A Randomized, Double-Blind, Placebo-Controlled Trial Of The Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy Symptoms In Subjects With Advanced Colorectal Cancer Terminated NCT00380874 Phase 4 Pregabalin;Placebo
45 Precision Spinal Cord Stimulation for Painful Diabetic Neuropathy Terminated NCT00487981 Phase 4
46 Pilot Study of L-Carnitine Supplementation in the Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Metastatic Breast Cancer Terminated NCT00754767 Phase 4 L-carnitine L-tartrate
47 Intelligent Activity-based Client-centred Training Unknown status NCT02982811 Phase 3
48 Phase 3 Study to Evaluate Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients. Unknown status NCT00872352 Phase 3
49 Use of Topical Lidocaine (Lidoderm 5% Patch) to Reduce Pain in Patients With Diabetic Neuropathy: Does the Density and Subtype of Sodium Channels Affect Response? Unknown status NCT01086150 Phase 2, Phase 3
50 Study of Topical Preparation of Capsaicin Nanoparticle in Patient With Painful Diabetic Neuropathy Unknown status NCT01125215 Phase 2, Phase 3 0.75% capsaicin nanoparticle cream;Placebo

Search NIH Clinical Center for Nervous System Disease

Cochrane evidence based reviews: nervous system diseases

Genetic Tests for Nervous System Disease

Anatomical Context for Nervous System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Nervous System Disease:

19
Central Nervous System, Peripheral Nervous System

MalaCards organs/tissues related to Nervous System Disease:

40
Brain, Breast, Bone, Spinal Cord, Testes, Heart, T Cells

Publications for Nervous System Disease

Articles related to Nervous System Disease:

(show top 50) (show all 2284)
# Title Authors PMID Year
1
Fingolimod (FTY720) improves postoperative cognitive dysfunction in mice subjected to D-galactose-induced aging. 61
31960817 2020
2
Extracellular vesicles in the diagnosis and treatment of central nervous system diseases. 61
31638080 2020
3
Is the Arginase Pathway a Novel Therapeutic Avenue for Diabetic Retinopathy? 61
32033258 2020
4
A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study. 61
32009149 2020
5
Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies. 61
31914899 2020
6
Transcriptome analysis of fibroblasts from schizophrenia patients reveals differential expression of schizophrenia-related genes. 61
31959813 2020
7
Autophagy in Myelinating Glia. 61
31744863 2020
8
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. 61
31994023 2020
9
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. 61
31390162 2020
10
Autophagy activation is required for homocysteine-induced apoptosis in bovine aorta endothelial cells. 61
32021943 2020
11
Microvascular pericytes in brain-associated vascular disease. 61
31743876 2020
12
Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist for Use in Central Nervous System Disease Models. 61
31904232 2020
13
Progress of Induced Pluripotent Stem Cell Technologies to Understand Genetic Epilepsy. 61
31940887 2020
14
A Central Nervous System Disease of Unknown Cause That Occurred in the Minamata Region: Results of an Epidemiological Study. 61
31685726 2020
15
Identification of potential natural neuroprotective molecules for Parkinson's disease by using chemoinformatics and molecular docking. 61
32028110 2020
16
[Systematic review of the treatment of spasticity in acquired adult brain damage]. 61
32007183 2020
17
Neuroprotective effects of isoquercitrin in diabetic neuropathy via Wnt/β-catenin signaling pathway inhibition. 61
31960520 2020
18
Synergy between plasminogen activator inhibitor-1, α-synuclein, and neuroinflammation in Parkinson's disease. 61
32035284 2020
19
Long non-coding RNA GAS5 promotes PC12 cells differentiation into Tuj1-positive neuron-like cells and induces cell cycle arrest. 61
31397350 2019
20
Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease. 61
30537919 2019
21
Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the campus all network. 61
31879328 2019
22
Meta-transcriptomic identification of hepatitis B virus in cerebrospinal fluid in patients with central nervous system disease. 61
31451314 2019
23
Neonatal Herpes Simplex Virus-1 Recurrence with Central Nervous System Disease in Twins after Completion of a Six-Month Course of Suppressive Therapy: Case Report. 61
31887772 2019
24
[Research progress on the effects of plateau hypoxia on blood-brain barrier structure and drug permeability]. 61
31955542 2019
25
Vaccine Oka Varicella Meningitis in Two Adolescents. 61
31776194 2019
26
Neuron specific enolase as a marker of seizure related neuronal injury. 61
31404559 2019
27
Expert insights: The potential role of the gut microbiome-bile acid-brain axis in the development and progression of Alzheimer's disease and hepatic encephalopathy. 61
31808182 2019
28
Inflammatory monocytes and neutrophils regulate Streptococcus suis-induced systemic inflammation and disease but are not critical for the development of central nervous system disease in a mouse model of infection. 61
31818962 2019
29
GINS complex subunit 2 (GINS2) plays a protective role in alcohol-induced brain injury. 61
30513217 2019
30
miR-29a Promotes the Neurite Outgrowth of Rat Neural Stem Cells by Targeting Extracellular Matrix to Repair Brain Injury. 61
31885334 2019
31
Measuring Motor Fatigability in the Upper Limbs in Individuals With Neurologic Disorders: A Systematic Review. 61
31891710 2019
32
Computer-Aided Tinnitus Detection based on Brain Network Analysis of EEG Functional Connectivity. 61
32039100 2019
33
MiR-20b-5p relieves neuropathic pain by targeting Akt3 in a chronic constriction injury rat model. 61
31381191 2019
34
The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population. 61
31520790 2019
35
Lack of Efficacy of High-Titered Immunoglobulin in Patients with West Nile Virus Central Nervous System Disease. 61
31625835 2019
36
A case of infratentorial meningioma causing spontaneous downbeat nystagmus. Case report and review of literatures. 61
31790839 2019
37
Development of an immunochromatographic device to detect antibodies for rapid diagnosis of human angiostrongyliasis. 61
31690362 2019
38
PARP-1 mediated cell death is directly activated by ZIKV infection. 61
31539774 2019
39
[A review on muscle-specific microRNAs as the biomarker for Duchenne muscular dystrophy]. 61
31753100 2019
40
Predictors of damage accrual in systemic lupus erythematosus: a longitudinal observational study with focus on neuropsychological factors and anti-neuronal antibodies. 61
31367942 2019
41
The Spatial and Temporal Characters of Demyelination and Remyelination in the Cuprizone Animal Model. 61
31251832 2019
42
SOME CLINICAL, NEUROLOGICAL AND NEUROPSYCHOLOGICAL CHARACTERISTICS OF PATIENTS WITH CHRONIC KIDNEY DISEASE. 61
31889708 2019
43
Utility of Surface and Blood Polymerase Chain Reaction Assays in Identifying Infants With Neonatal Herpes Simplex Virus Infection. 61
31626049 2019
44
Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis. 61
31008556 2019
45
Large animal models contribute to the development of therapies for central and peripheral nervous system dysfunction in patients with lysosomal storage diseases. 61
31384936 2019
46
Central nervous system disease in childhood acute lymphoblastic leukemia. 61
26990196 2019
47
[β Amyloid Hypothesis in Alzheimer's Disease:Pathogenesis,Prevention,and Management]. 61
31699204 2019
48
Impact of Travel Distance on Radiation Treatment Modality for Central Nervous System Disease. 61
31831978 2019
49
The assessment of lenticulostriate arteries originating from middle cerebral artery using ultra high-field magnetic resonance time-of-flight angiography. 61
31331750 2019
50
Glial Fibrillary Acidic Protein (GFAP) Autoimmunity in the Setting of Seropositive Rheumatoid Arthritis Treated With Etanercept. 61
31478999 2019

Variations for Nervous System Disease

ClinVar genetic disease variations for Nervous System Disease:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;X;t(Y;3)(p11.2;p12.3)dnTranslocation Likely pathogenic 267818
2 46;XY;t(1;3)(q32.3;q21.1)Translocation Uncertain significance 267980

Expression for Nervous System Disease

Search GEO for disease gene expression data for Nervous System Disease.

Pathways for Nervous System Disease

Pathways related to Nervous System Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 TNF NOS2 IL6 IL1B IFNG CXCR3
2
Show member pathways
13.38 TNF NOS2 MMP9 IL6 IL1B IFNG
3
Show member pathways
13.33 TNF IL6 IL1B CXCR3 CSF2 CCR6
4
Show member pathways
13.14 TNF TBK1 NOS2 MMP9 IL6 IL1B
5
Show member pathways
12.95 TNF TBK1 IL6 IL1B CSF2 CCR1
6
Show member pathways
12.83 TNF TBK1 IL6 IL1B IFNG
7 12.81 TNF TBK1 IL6 IL1B IFNG
8
Show member pathways
12.78 TNF TBK1 IL6 IL1B IFNG
9
Show member pathways
12.62 TNF IL6 IL1B IFNG CSF2
10
Show member pathways
12.61 TNF NOS2 IL6 IL1B IFNG
11 12.4 TNF TBK1 IL1B CSF2
12
Show member pathways
12.37 TNF IL6 CXCR3 CCR6 CCR1
13
Show member pathways
12.36 TNF SERPINA3 IL6 IL1B IFNG
14
Show member pathways
12.34 TNF NOS2 IL6 IL1B IFNG
15
Show member pathways
12.29 TNF NOS2 IL1B IFNG
16 12.28 PROM1 MMP9 IL6 CSF2
17 12.27 TNF NOS2 IL6 IL1B IFNG
18 12.26 TNF TBK1 IL6 IL1B
19
Show member pathways
12.25 TNF NOS2 IL6 IL1B
20
Show member pathways
12.24 TNF IL1B IFNG H2AC18
21 12.23 TNF NOS2 MMP9 IL6 IFNG
22
Show member pathways
12.22 TNF NOS2 IL6 IL1B IFNG
23
Show member pathways
12.2 TNF TBK1 MMP9 IL6 IL1B IFNG
24 12.12 TNF MMP9 IL1B IFNG
25
Show member pathways
12.08 TNF IL6 IL1B IFNG
26 12.04 TNF IL6 IFNG CSF2 CCR1
27 12.03 TNF TBK1 IL6 IL1B
28 12.02 TNF NOS2 MMP9 IL6 IL1B
29
Show member pathways
12.01 TNF MMP9 IL6 IL1B IFNG CSF2
30 12 TNF MMP9 IL6 IL1B CSF2
31 11.93 TNF IL6 IL1B CSF2
32 11.92 TNF NOS2 MMP9 IL6 IL1B IFNG
33 11.89 TNF IL6 IL1B IFNG CSF2
34 11.82 IL6 IFNG CSF2
35 11.81 NOS2 IL6 IL1B IFNG CSF2
36 11.8 TNF NOS2 IL6 IL1B
37 11.8 TNF IL1B IFNG CXCR3 CCR6
38
Show member pathways
11.78 TNF IFNG CSF2
39 11.74 TNF IL6 IL1B IFNG CSF2
40 11.74 TNF NOS2 IL6 IL1B IFNG CSF2
41 11.65 TNF MMP9 IL6 IL1B CSF2
42 11.64 TNF IL6 IL1B
43 11.62 NOS2 IL6 IFNG
44 11.6 TNF IL6 IL1B IFNG
45 11.58 TNF IL6 IFNG
46 11.57 TNF NOS2 IL1B IFNG
47 11.55 IL6 IL1B CSF2
48 11.55 TNF IL1B IFNG
49 11.54 TNF MMP9 IL6
50 11.54 TNF IL6 IL1B IFNG

GO Terms for Nervous System Disease

Cellular components related to Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 TNF MOG CXCR3 CCR6 CCR1

Biological processes related to Nervous System Disease according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.04 TNF IL6 IL1B IFNG CSF2
2 negative regulation of gene expression GO:0010629 9.97 TNF TBK1 NOS2 IFNG CCR1
3 positive regulation of protein phosphorylation GO:0001934 9.93 TNF MMP9 IL1B IFNG
4 cellular response to lipopolysaccharide GO:0071222 9.85 TNF NOS2 IL6 IL1B CSF2
5 chemokine-mediated signaling pathway GO:0070098 9.83 CXCR3 CCR6 CCR1
6 positive regulation of interleukin-6 production GO:0032755 9.81 TNF IL6 IL1B
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNF IL6 IFNG CSF2
8 inflammatory response GO:0006954 9.8 TNF TBK1 SERPINA3 IL6 IL1B CXCR3
9 positive regulation of phagocytosis GO:0050766 9.78 TNF IL1B IFNG
10 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 TNF IL1B IFNG
11 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.76 TNF IL1B CSF2
12 immune response GO:0006955 9.76 TNF IL6 IL1B IFNG CXCR3 CSF2
13 negative regulation of neurogenesis GO:0050768 9.74 TNF IL6 IL1B
14 regulation of insulin secretion GO:0050796 9.73 TNF NOS2 IL1B IFNG
15 positive regulation of osteoclast differentiation GO:0045672 9.71 TNF IFNG CCR1
16 positive regulation of glial cell proliferation GO:0060252 9.7 TNF IL6 IL1B
17 astrocyte activation GO:0048143 9.69 TNF IL1B IFNG
18 humoral immune response GO:0006959 9.67 TNF IL6 IFNG CCR6
19 negative regulation of amyloid-beta clearance GO:1900222 9.66 TNF IFNG
20 regulation of neuroinflammatory response GO:0150077 9.65 MMP9 IL6
21 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
22 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 TNF IL1B IFNG
23 regulation of establishment of endothelial barrier GO:1903140 9.63 TNF IL1B
24 positive regulation of killing of cells of other organism GO:0051712 9.62 NOS2 IFNG
25 positive regulation of interleukin-23 production GO:0032747 9.62 IFNG CSF2
26 positive regulation of fever generation GO:0031622 9.61 TNF IL1B
27 sequestering of triglyceride GO:0030730 9.59 TNF IL1B
28 positive regulation of neuroinflammatory response GO:0150078 9.58 TNF IL6 IL1B
29 positive regulation of vitamin D biosynthetic process GO:0060557 9.56 TNF IFNG
30 positive regulation of nitrogen compound metabolic process GO:0051173 9.55 TNF IFNG
31 positive regulation of chemokine biosynthetic process GO:0045080 9.5 TNF IL1B IFNG
32 cytokine-mediated signaling pathway GO:0019221 9.17 TNF NOS2 MMP9 IL6 IL1B CSF2
33 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.13 TNF IL1B IFNG

Molecular functions related to Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine binding GO:0019956 9.5 CXCR3 CCR6 CCR1
2 C-C chemokine binding GO:0019957 9.43 CXCR3 CCR6 CCR1
3 C-C chemokine receptor activity GO:0016493 9.33 CXCR3 CCR6 CCR1
4 chemokine receptor activity GO:0004950 9.13 CXCR3 CCR6 CCR1
5 cytokine activity GO:0005125 9.02 TNF IL6 IL1B IFNG CSF2

Sources for Nervous System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....